Abstract
Supplementary Figure S1. Tumor-infiltrating CD8+ cell was positive correlation to efficacy of the combined DNMT inhibition and anti-PD-1 mAb therapy. Supplementary Figure S2. No significant reduction in body weight of EL4 tumor-bearing mice with anti-PD-1 treatment. Supplementary Figure S3. Gating strategies for Figure 2D-F. Supplementary Figure S4. PD-L1 and PD-1 expression in pre-clinical models. Supplementary Figure S5. Immune related pathways were downregulated in EL4 P3 tumor. Supplementary Figure S6. No significant reduction in body weight of EL4 P3 tumor-bearing mice under different treatment. Supplementary Figure S7. DNMT inhibitors enhance CD8+ T cell activated and cytotoxicity in vivo. Supplementary Figure S8. DNMT inhibitors treatment did not affect PD-L1 expression in pre-clinical models. Supplementary Figure S9. DNMT inhibitors induce MHC-I and ISGs expression in EL4 cells. Supplementary Figure S10. IFNAR1 blockade attenuated the antitumor immunity induced by the combination of DAC and α-PD-1. Supplementary Figure S11. STING knockdown did not impair DNMT inhibitors induced CD8+ T cells activity. Supplementary Figure S12. DNMT inhibitors induces ERVs expression in human NKTL cells.